| Name | Title | Contact Details |
|---|
Tottenham Hotspur is a world-famous football club based in London. On the pitch, the Club competes in the upper echelons of the English Premier League and is a regular participant in marque UEFA club competitions. Off the pitch, the Club has a strong and successful business model centered around building a platform for long-term success, which includes a world-class training centre and now a brand new 62,214 seater world-class stadium. The Club operates out of multiple sites, including its Headquarters at Lilywhite House adjacent to the Tottenham Hotspur Stadium, the Training Centre, our state-of-the-art training facilities in Enfield or the Warehouse, the home of our Retail and Merchandise division in Brimsdown Were so proud of our rich history. From humble beginnings in North London, we became the first and, to date, only non-league side to win the FA Cup in 1901 – the first of eight triumphs in the age-old, world-renowned competition thus far.
Unlocking Your Businesss Full Potential with AI At AI Nomics, were driven by the vision to revolutionize your business approach. Our mission is to empower you to take on your operations with AI by your side, helping you overcome challenges and achieve your goals faster than ever before. How We Transform Your Business: The AI Nomics Approach Were here to make sure you spend more time doing what you love and less time on the mundane. Our framework is designed for smooth AI integration to address your needs and accelerate your success: The 4 As of AI Integration: 1. Analyze: We identify areas where AI can have the greatest impact and help define your goals. 2. Automate: We pinpoint repetitive tasks suitable for automation to save you time. 3. Augment: We find opportunities where AI can enhance your efficiency in crucial tasks. 4. Activate: We seamlessly integrate and activate tailored AI solutions into your operations. The AI Business Suite: Tools Tailored for Transformation Our AI Business Suite offers a range of smart tools designed for seamless integration, allowing you to harness the full benefits of AI effortlessly: • CustomerCare AI: Transform your customer interactions with an AI that handles queries and personalizes responses around the clock. • SalesBooster: Equip your site with a virtual sales expert that turns visitors into sales, any time of day. • LeadNova: Enhance your outreach with AI that personalizes communication and efficiently converts prospects into loyal customers. Get Started Now on your AI transformation journey: Claim your free AI consultation in our bio!
Johnson & Johnson is a multinational healthcare company founded in 1886 in New Brunswick, New Jersey. The company is dedicated to improving human health and well-being through its innovative products and services. Johnson & Johnson operates in three main segments. The Consumer Health segment includes popular brands like Band-Aids, Tylenol, and Johnsons baby products, offering a variety of personal care and over-the-counter medications. The Pharmaceuticals division develops prescription drugs across therapeutic areas such as immunology, infectious diseases, and oncology. Lastly, the Medical Devices segment focuses on creating and manufacturing devices and diagnostics for surgical procedures, orthopedics, and vision care. The companys products cater to a wide audience, including consumers, healthcare professionals, and medical institutions, ensuring accessibility and support for various health needs.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.